entertainment -WSS

entertainment

author：fashion 2025-09-27 09:40:46 - browse：6

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： In medicine, common shorthands can shortchange care

WSS

3 medical device trends to watch in 2024

GSK Flovent asthma inhalers replaced by authorized generics

U.K. sequencing study surfaces new findings about tumor DNA

AdventHealth escalates lawsuit against insurance vendor Multiplan

The biotech scorecard for Q1: 17 stock

The FDA must approve intranasal treatments for anaphylaxis

knowledge

entertainment

leisure time

Bright Health sells Medicare Advantage business to Molina

White House finalizes ITC's import ban of latest Apple Watches

Apple is now the first public company to be valued at $3 trillion

A single drug, study failures leave Anavex with nothing but cash

Guidelines to prevent youth baseball injuries need more muscle

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Activists slam private health insurers over coverage restrictions

https://cbu01.alicdn.com/img/ibank/2017/068/481/4438184860_1190265550.220x220xz.jpg

Moonlake's readout produced a cash windfall. Risks remain

Ahead of JPM, here's who's profiting most in health care

leisure time

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Goldman Sachs launches $650M fund for life science investments

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

At least 12 people were injured in a blast at a port in northwest Turkey

How a scoliosis diagnosis changed the life of one young dancer

Wikipedia

hotspot

hotspot

focus